
Biotech firm Elicio Therapeutics' ELTX.O shares fall 14% to an over 2-month low of $6.71
ELTX now expects mid-stage study data of its lead experimental vaccine, ELI-002, in Q3 2025 vs. previous expectation of H1 2025
Co is testing vaccine against certain types of solid tumors that are caused by mutations in the KRAS gene, which are common in pancreatic, colorectal, and non-small cell lung cancers
ELTX's net loss also widens in 2024 compared with 2023
As of last close, ELTX has risen 2.5% in the past 12 months